Your browser doesn't support javascript.
loading
Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study.
Pérez de Llano, Luis A; Cosío, Borja G; Domingo, Christian; Urrutia, Isabel; Bobolea, Irina; Valero, Antonio; Entrenas Costa, Luis M; Quirce, Santiago; Barranco, Pilar; Marina Malanda, Nuria; Andrés, Luis Prieto; Alvarez-Gutiérrez, Francisco J.
Afiliação
  • Pérez de Llano LA; Pneumology Service, Hospital Universitario Lucus Agusti, Lugo, Spain. Electronic address: eremos26@hotmail.com.
  • Cosío BG; Department of Respiratory Medicine, Hospital Universitario Son Espases-IdISBa, Palma de Mallorca, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
  • Domingo C; Department of Pulmonary Medicine, Corporació Sanitària Parc Taulí, Sabadell, Spain; Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain.
  • Urrutia I; Asthma Unit, Department of Pulmonary Medicine, Hospital Galdakao, Bizkaia, Spain.
  • Bobolea I; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Allergy Section, Department of Pulmonology and Allergy, Hospital Clinic Barcelona-Institute for Health Research (IdiBAPS), Madrid, Spain.
  • Valero A; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Allergy Section, Department of Pulmonology and Allergy, Hospital Clinic Barcelona-Institute for Health Research (IdiBAPS), Madrid, Spain.
  • Entrenas Costa LM; Pneumology Service, Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, Córdoba, Spain.
  • Quirce S; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
  • Barranco P; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
  • Marina Malanda N; Department of Pulmonology, Hospital de Cruces, Bilbao, Spain.
  • Andrés LP; Allergy Section, Hospital Universitario Dr Peset, Valencia, Spain.
  • Alvarez-Gutiérrez FJ; Asthma Unit, Hospital Universitario Virgen del Rocío, Seville, Spain.
J Allergy Clin Immunol Pract ; 7(7): 2277-2283.e2, 2019.
Article em En | MEDLINE | ID: mdl-30677539
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma / Antiasmáticos / Anticorpos Monoclonais Humanizados / Omalizumab Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma / Antiasmáticos / Anticorpos Monoclonais Humanizados / Omalizumab Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article